Pharma: Page 20
-
Courtesy of Roche
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
CEO Thomas Schinecker claimed the company has “many opportunities” to stand out in the competitive field, and can get to market “much faster” than investors expect.
By Ben Fidler • July 25, 2024 -
Courtesy of Sanofi
Sanofi’s immunology bet starts to pay off
Some analysts described Sanofi’s pipeline of immune system therapies, which includes more than half a dozen drugs in mid- to late-stage testing, as “underappreciated” by investors.
By Jacob Bell • July 25, 2024 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Getty Images
Pfizer says hemophilia gene therapy meets late-stage study goal
While the study results were positive, questions remain about the longer-term potential of hemophilia treatments like Pfizer’s.
By Kristin Jensen • July 24, 2024 -
Getty Images
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
The Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.” Elsewhere, Geron is losing its commercial chief and Biovectra will sell to Agilent for $925 million.
By BioPharma Dive staff • July 24, 2024 -
Kena Betancur via Getty Images
Merck claims late-stage study success for RSV antibody
The drug, a rival to Sanofi and AstraZeneca’s fast-selling Beyfortus, met its main goals in a Phase 3 trial. But undisclosed study results leave its full potential unclear.
By Ben Fidler • Updated July 23, 2024 -
Mario Tama via Getty Images
J&J seeks expanded approval for antidepressant Spravato
The company is seeking a monotherapy approval for Spravato, sales of which have climbed in recent quarters.
By Delilah Alvarado • July 22, 2024 -
shutterstock.com/TippaPatt
Sponsored by VeradigmClinical data registries: Transforming the future of medical research
Clinical data registries have become invaluable for generating unique insights for life sciences. Read on to learn more.
By Amanda Cohen, MPH • July 22, 2024 -
Anthony Kwan / Stringer via Getty Images
Global tech outage hits US hospitals
At least 11 health systems were experiencing issues Friday after an update by cybersecurity firm CrowdStrike went awry.
By Susanna Vogel • Updated July 19, 2024 -
Getty Images
Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.
By BioPharma Dive staff • July 19, 2024 -
Mario Tama via Getty Images
Brain drug revivalIn strengthening Spravato sales, a positive sign for psychedelic drugs
Jefferies analyst Andrew Tsai views growing sales for J&J’s depression treatment as evidence that psychedelics like it can be commercially viable.
By Ned Pagliarulo • Updated July 23, 2024 -
Courtesy of Roche
Obesity pill from Roche shows promising weight loss in small study
Treatment led to "clinically meaningful" weight loss over four weeks, but longer studies will be needed to compare it to Wegovy and Zepbound.
By Jonathan Gardner • July 17, 2024 -
Getty Images
Caribou lays off staff; Roche walks away from Relay
Caribou is slashing its workforce by 12%. Elsewhere, a CDMO is investing in GLP-1 drug demand and Beam’s CFO is returning to J.P. Morgan.
By BioPharma Dive staff • July 17, 2024 -
Justin Sullivan via Getty Images
Gilead’s CMO to depart next year
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.
By Ned Pagliarulo • July 17, 2024 -
Getty Images
Leqembi sales inch higher; Spark’s pivot leads to layoffs
Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, a well-funded DNA sequencing startup landed one of the year’s larger private funding rounds.
By BioPharma Dive staff • July 12, 2024 -
Courtesy of BMS
Bristol Myers’ leukemia blockbuster set to face generic rivals
Patent litigation has opened the door to generic copies of Bristol Myers’ Sprycel arriving in the U.S. as soon as September.
By Amy Baxter • July 12, 2024 -
Getty Images
Pfizer thinks it found its obesity pill
Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.
By Jacob Bell • July 11, 2024 -
Getty Images
Novo’s once-weekly insulin rejected by FDA
The FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes treatment in late-stage testing.
By Kristin Jensen • July 11, 2024 -
Getty Images
AbbVie names new R&D head; Arcutis eczema cream approved
Roopal Thakkar will succeed Tom Hudson as AbbVie’s top scientist. Elsewhere, Skyhawk is advancing its Huntington’s drug and Zevra is preparing for an FDA advisory committee meeting.
By BioPharma Dive staff • July 10, 2024 -
Jeenah Moon via Getty Images
Pfizer research chief Dolsten to step down, with company at a crossroads
The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals but also some notable setbacks during his time as Pfizer’s top scientist.
By Ben Fidler • July 9, 2024 -
Getty Images
Lilly to buy Morphic in $3B bet on inflammation drug
The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.
By Jacob Bell • July 8, 2024 -
Getty Images
Ligand to buy Apeiron; Roche reports another TIGIT setback
Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.
By BioPharma Dive staff • July 8, 2024 -
Courtesy of CureVac
CureVac cuts jobs, licenses out vaccines to GSK
The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.
By Jacob Bell • July 3, 2024 -
Getty Images
Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
Forbion led the startup’s Series B round. Elsewhere, Vertex got an FDA decision date for its “vanza triple” and Dupixent won a marketing green light in Europe for COPD.
By BioPharma Dive staff • July 3, 2024 -
Courtesy of Eisai
Eisai and Bristol Myers cancel cancer ADC deal
The Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.
By Jonathan Gardner • July 1, 2024 -
Getty Images
Sponsored by Nelson LabsThe right viral safety program can guard against costly bioburden incidents in biopharma development
Viral contamination threatens biopharmaceutical development, making viral clearance and safety essential for risk mitigation.
July 1, 2024
Previous
